Maternal medication and herbal use and risk for hypospadias: Data from the National Birth Defects Prevention Study, 1997-2007

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 7, 2013, Pages 783-793

  Lind, Jennifer N ^a   Tinker, Sarah C ^a   Broussard, Cheryl S ^a   Reefhuis, Jennita ^a   Carmichael, Suzan L ^b   Honein, Margaret A ^a   Olney, Richard S ^a   Parker, Samantha E ^c   Werler, Martha M ^c  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b STANFORD UNIVERSITY   (United States)

^c BOSTON UNIVERSITY   (United States)

Author keywords

Birth defects; Drug safety; Herbal; Hypospadias; Medication; Pharmacoepidemiology; Pregnancy

Indexed keywords

ACETYLSALICYLIC ACID; AZITHROMYCIN; BUTALBITAL; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; ESTROGEN; FOLLITROPIN; HERBACEOUS AGENT; IBUPROFEN; ILLICIT DRUG; LABETALOL; LEUPRORELIN; LEVOTHYROXINE SODIUM; NON PRESCRIPTION DRUG; PARACETAMOL; PHENYLPROPANOLAMINE; PROGESTERONE; VENLAFAXINE;

ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG USE; EDUCATIONAL STATUS; ETHNIC DIFFERENCE; EXPLORATORY RESEARCH; FEMALE; FEMALE SUBFERTILITY; FIRST TRIMESTER PREGNANCY; HERBAL MEDICINE; HUMAN; HYPOSPADIAS; INFANT; LIVE BIRTH; MAJOR CLINICAL STUDY; MALE; MATERNAL AGE; MULTICENTER STUDY; POPULATION BASED CASE CONTROL STUDY; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; RACE DIFFERENCE;

BIRTH DEFECTS; DRUG SAFETY; HERBAL; HYPOSPADIAS; MEDICATION; PHARMACOEPIDEMIOLOGY; PREGNANCY;

ADULT; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; DRUG UTILIZATION REVIEW; FEMALE; FERTILITY AGENTS; HUMANS; HYPOSPADIAS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; NONPRESCRIPTION DRUGS; ODDS RATIO; PHARMACOEPIDEMIOLOGY; PHARMACOVIGILANCE; PHYTOTHERAPY; PLANT PREPARATIONS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PRESCRIPTION DRUGS; RISK ASSESSMENT; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; UNITED STATES;

EID: 84880028211     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3448     Document Type: Article

References (52)

1. Chambers CD, Polifka JE, Friedman JM. Drug safety in pregnant women and their babies: ignorance not bliss. Clin Pharmacol Ther 2008; 83(1):181-3. DOI: 10.1038/sj.clpt.6100448
2. Glover DD, Amonkar M, Rybeck BF, Tracy TS. Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. Am J Obstet Gynecol 2003; 188(4): 1039-45. DOI: 10.1067/mob.2003.223
3. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernandez-Diaz S, National Birth Defects Prevention Study. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011; 205(1): 51 e1-8 DOI: 10.1016/j.ajog.2011.02.029
4. Refuerzo JS, Blackwell SC, Sokol RJ, et al. Use of over-the-counter medications and herbal remedies in pregnancy. Am J Perinatol 2005; 22(6): 321-4. DOI: 10.1055/s-2005-873235
5. Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA. Use of over-the-counter medications during pregnancy. Am J Obstet Gynecol 2005; 193(3 Pt 1): 771-7. DOI: 10.1016/j.ajog.2005.02.100
6. Black RA, Hill DA. Over-the-counter medications in pregnancy. Am Fam Physician 2003; 67(12): 2517-24.
7. Broussard CS, Louik C, Honein MA, Mitchell AA, National Birth Defects Prevention Study. Herbal use before and during pregnancy. Am J Obstet Gynecol 2010; 202(5): 443 e1-6. DOI: 10.1016/j.ajog.2009.10.865
8. Paulozzi LJ, Erickson JD, Jackson RJ. Hypospadias trends in two US surveillance systems. Pediatrics 1997; 100(5): 831-4. DOI: 10.1542/peds.100.5.831
9. Carmichael SL, Shaw GM, Lammer EJ. Environmental and genetic contributors to hypospadias: a review of the epidemiologic evidence. Birth Defects Res A Clin Mol Teratol 2012; 94(7): 499-510. DOI: 10.1002/bdra.23021
10. Stokowski LA. Hypospadias in the neonate. Adv Neonatal Care 2004; 4(4): 206-15. DOI: 10.1016/j.adnc.2004.05.003
11. Anderka M, Mitchell AA, Louik C, Werler MM, Hernandez-Diaz S, Rasmussen SA, National Birth Defects Prevention Study. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth Defects Res A Clin Mol Teratol 2012; 94(1): 22-30. DOI: 10.1002/bdra.22865
12. Carmichael SL, Shaw GM, Laurent C, Croughan MS, Olney RS, Lammer EJ. Maternal progestin intake and risk of hypospadias. Arch Pediatr Adolesc Med 2005; 159(10): 957-62. DOI: 10.1001/archpedi.159.10.957
13. Czeizel AE, Kazy Z, Puho E. A population-based case-control teratological study of oral nystatin treatment during pregnancy. Scand J Infect Dis 2003; 35(11-12): 830-5. DOI: 10.1080/00365540310017069
14. Rodriguez-Pinilla E, Mejias C, Prieto-Merino D, Fernandez P, Martinez-Frias ML, Group EW. Risk of hypospadias in newborn infants exposed to valproic acid during the first trimester of pregnancy: a case-control study in Spain. Drug Saf 2008; 31(6): 537-43. DOI: 10.2165/00002018-200831060-00008
15. Yoon PW, Rasmussen SA, Lynberg MC, et al. The National Birth Defects Prevention Study. Public Health Rep 2001; 116(Suppl 1): 32-40. DOI: 10.1093/phr/116.S1.32
16. Rasmussen SA, Olney RS, Holmes LB, Lin AE, Keppler-Noreuil KM, Moore CA, National Birth Defects Prevention Study. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 2003; 67(3): 193-201. DOI: 10.1002/bdra.10012
17. Friedman JM. The use of dysmorphology in birth defects epidemiology. Teratology 1992; 45(2): 187-93. DOI: 10.1002/tera.1420450212
18. Khoury MJ, James LM, Flanders WD, Erickson JD. Interpretation of recurring weak associations obtained from epidemiologic studies of suspected human teratogens. Teratology 1992; 46(1): 69-77. DOI: 10.1002/tera.1420460110
19. Khoury MJ, Moore CA, James LM, Cordero JF. The interaction between dysmorphology and epidemiology: methodologic issues of lumping and splitting. Teratology 1992; 45(2): 133-8. DOI: 10.1002/tera.1420450206
20. National Heart L, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Vol. NIH Publication No. 98-4083 National Institutes of Health, 1998.
21. Fredell L, Kockum I, Hansson E, et al. Heredity of hypospadias and the significance of low birth weight. J Urol 2002; 167(3): 1423-7. DOI: 10.1016/S0022-5347(05)65334-7
22. Schnack TH, Zdravkovic S, Myrup C, et al. Familial aggregation of hypospadias: a cohort study. Am J Epidemiol 2008; 167(3): 251-6. DOI: 10.1093/aje/kwm317
23. Carmichael SL, Ma C, Werler MM, Olney RS, Shaw GM, National Birth Defects Prevention Study. Maternal corticosteroid use and hypospadias. J Pediatr 2009; 155(1): 39-44, 44 e1. DOI: 10.1016/j.jpeds.2009.01.039
24. Fredell L, Lichtenstein P, Pedersen NL, Svensson J, Nordenskjold A. Hypospadias is related to birth weight in discordant monozygotic twins. J Urol 1998; 160(6 Pt 1): 2197-9. DOI: 10.1016/S0022-5347(01)62294-8
25. Main KM, Jensen RB, Asklund C, Hoi-Hansen CE, Skakkebaek NE. Low birth weight and male reproductive function. Horm Res 2006; 65(Suppl 3): 116-22. DOI: 10.1159/000091516
26. Meijer WM, de Jong-Van den Ber LT, van den Ber MD, Verheij JB, de Walle HE. Clomiphene and hypospadias on a detailed level: signal or chance?. Birth Defects Res A Clin Mol Teratol 2006; 76(4): 249-52. DOI: 10.1002/bdra.20243
27. Reefhuis J, Honein MA, Schieve LA, Rasmussen SA, National Birth Defects Prevention Study. Use of clomiphene citrate and birth defects, National Birth Defects Prevention Study, 1997-2005. Hum Reprod 2011; 26(2): 451-7. DOI: 10.1093/humrep/deq313
28. Lacy CF, Armstrong LL, Goldman MP. Drug Information Handbook: 2006-2007. 14 ed Lexi-Comp, Hudson, OH, USA 2006.
29. Gupta C, Goldman AS. The arachidonic acid cascade is involved in the masculinizing action of testosterone on embryonic external genitalia in mice. Proc Natl Acad Sci U S A 1986; 83(12): 4346-9. DOI: 10.1073/pnas.83.12.4346
30. Hernandez RK, Werler MM, Romitti P, Sun L, Anderka M, National Birth Defects Prevention Study. Nonsteroidal antiinflammatory drug use among women and the risk of birth defects. Am J Obstet Gynecol 2012; 206(3):228 e1-8. DOI: 10.1016/j.ajog.2011.11.019
31. Baskin LS. Hypospadias. Adv Exp Med Biol 2004; 545: 3-22. DOI: 10.1007/978-1-4419-8995-6_1
32. Carmichael SL, Shaw GM, Laurent C, Olney RS, Lammer EJ, National Birth Defects Prevention Study. Maternal reproductive and demographic characteristics as risk factors for hypospadias. Paediatr Perinat Epidemiol 2007; 21(3): 210-8. DOI: 10.1111/j.1365-3016.2007.00809.x
33. Reefhuis J, Honein MA, Schieve LA, Correa A, Hobbs CA, Rasmussen SA, National Birth Defects Prevention Study. Assisted reproductive technology and major structural birth defects in the United States. Hum Reprod 2009; 24(2): 360-6. DOI: 10.1093/humrep/den387
34. Corchia C, Mastroiacovo P, Lanni R, Mannazzu R, Curro V, Fabris C. What proportion of multiple births are due to ovulation induction? A register-based study in Italy. Am J Public Health 1996; 86(6): 851-4. DOI: 10.2105/AJPH.86.6.851
35. Kallen B, Olausson PO, Nygren KG. Neonatal outcome in pregnancies from ovarian stimulation. Obstet Gynecol 2002; 100(3): 414-9. DOI: 10.1016/S0029-7844(02)02069-0
36. Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update 1997; 3(4): 359-65. DOI: 10.1093/humupd/3.4.359
37. Sovino H, Sir-Petermann T, Devoto L. Clomiphene citrate and ovulation induction. Reprod Biomed Online 2002; 4(3): 303-10. DOI: 10.1016/S1472-6483(10)61821-4
38. Lauder JM. Neurotransmitters as morphogens. Prog Brain Res 1988; 73: 365-387.
39. Buznikov GA, Lambert HW, Lauder JM. Serotonin and serotonin-like substances as regulatores of early embryogenesis and morphogenesis. Cell Tissue Res 2001; 305: 177-186.
40. Rampono J, Simmer K, Ilett KF, et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 2009; 42(3): 95-100. DOI: 10.1055/S-0028-1103296
41. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. Lippincott Williams & Wilkins, Philadelphia, PA, USA 2001. DOI: 10.1016/S1526-9523(03)00148-X
42. Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001; 158(10): 1728-30. DOI: 10.1176/appi.ajp.158.10.1728
43. Polen K, Rasmussen SA, Colarusso T, Reefhuis J. The association between reported venlafaxine use in early pregnancy and birth defects, National Birth Defects Prevention Study, 1997-2007. Birth Defects Res A Clin Mol Teratol 2013; 97(1): 28-35. DOI: 10.1002/bdra.23096
44. Werler M, McCloskey C, Edmonds LD, Olney RS, Honein MA, Reefhuis J. Evaluation of an association between loratadine and hypospadias - United States, 1997-2001. MMWR Morb Mortal Wkly Rep 2004; 53(10): 219-221. DOI: 10.1001/jama.291.15.1828
45. Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr Adolesc Med 2009; 163(11): 978-85. DOI: 10.1001/archpediatrics.2009.188
46. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM, National Birth Defects Prevention Study. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007; 356(26): 2684-92. DOI: 10.1056/NEJMoa066584
47. Bitsko RH, Reefhuis J, Louik C, et al., National Birth Defects Prevention Study. Periconceptional use of weight loss products including ephedra and the association with birth defects. Birth Defects Res A Clin Mol Teratol 2008; 82(8): 553-62. DOI: 10.1002/bdra.20472
48. Gilboa SM, Strickland MJ, Olshan AF, Werler MM, Correa A, National Birth Defects Prevention Study. Use of antihistamine medications during early pregnancy and isolated major malformations. Birth Defects Res A Clin Mol Teratol 2009; 85(2): 137-50. DOI: 10.1002/bdra.20513
49. Feldkamp ML, Meyer RE, Krikov S, Botto LD. Acetaminophen use in pregnancy and risk of birth defects: findings from the National Birth Defects Prevention Study. Obstet Gynecol 2010; 115(1): 109-15. DOI: 10.1097/AOG.0b013e3181c52616
50. Alwan S, Reefhuis J, Botto LD, Rasmussen SA, Correa A, Friedman JM, National Birth Defects Prevention Study. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol 2010; 203(1):52 e1-6. DOI: 10.1016/j.ajog.2010.02.015
51. Broussard CS, Rasmussen SA, Reefhuis J, et al., National Birth Defects Prevention Study. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol 2011; 204(4): 314 e1-11. DOI: 10.1016/j.ajog.2010.12.039
52. Caton AR, Bell EM, Druschel CM, et al., National Birth Defects Prevention Study. Maternal hypertension, antihypertensive medication use, and the risk of severe hypospadias. Birth Defects Res A Clin Mol Teratol 2008; 82(1): 34-40. DOI: 10.1002/bdra.20415